This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fenske, T. S. Articles by Graubert, T. A. Search for Related Content PubMed PubMed Citation Articles by Fenske, T. S. Articles by Graubert, T. A.

Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice

Departments of ¹ Internal Medicine, ² Anatomy and Neurobiology, and ³ Biostatistics, Washington University School of Medicine, St. Louis, Missouri; ⁴ The Jackson Laboratory, Bar Harbor, Maine; and ⁵ Department of Pathology, Division of Molecular Diagnostics, University of Pittsburgh, Pittsburgh, Pennsylvania

Requests for reprints: Timothy Graubert, Division of Oncology, Stem Cell Biology Section, Washington University School of Medicine, Campus Box 8007, 660 South Euclid Avenue, St. Louis, MO 63110. Phone: 314-747-4437; Fax: 314-362-9333; E-mail: graubert{at}medicine.wustl.edu.

Secondary malignancies are a serious adverse consequence of alkylator chemotherapy. The risk of developing an alkylator-associated malignancy is influenced by genetic background, although the relevant genetic factors are poorly understood. To screen for novel susceptibility factors, we established a mouse model of alkylator-induced malignancy. We exposed mice from 20 inbred strains to the prototypical alkylating agent, N-nitroso-N-ethylurea (ENU). ENU was a potent carcinogen in many of the strains tested, inducing 140 tumors in 240 ENU-treated mice (66% incidence of at least one tumor in evaluable mice), compared with a background incidence of 8% spontaneous tumors in 240 strain-, age-, and sex-matched control mice (relative risk, 8.4; P < 0.0001). A wide variety of tumor histologies were noted, including epithelial carcinomas, soft tissue sarcomas, and hematopoietic tumors. Cancer susceptibility was a heritable trait for the most common tumor types, lung adenocarcinoma (H² = 0.25), T cell lymphoma (H² = 0.19), and myeloid malignancies (H² = 0.10). Quantitative trait locus mapping identified regions on chromosomes 3, 6, 9, and 15 containing candidate genes associated with lung adenoma, lung carcinoma, and lymphoma susceptibility. This novel mouse model recapitulates many features of human alkylator-associated cancer and supports the hypothesis that susceptibility to this syndrome is influenced by inherited polymorphisms that could be used to make informed clinical treatment decisions. (Cancer Res 2006; 66(10): 5029-38)

This article has been cited by other articles:

				R. K. Funk, T. J. Maxwell, M. Izumi, D. Edwin, F. Kreisel, T. J. Ley, J. M. Cheverud, and T. A. Graubert Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice Blood, August 15, 2008; 112(4): 1434 - 1442. [Abstract] [Full Text] [PDF]

				M. J. Walter Del(5q): gene dosage matters Blood, July 15, 2007; 110(2): 473 - 474. [Full Text] [PDF]

				J. M. Joslin, A. A. Fernald, T. R. Tennant, E. M. Davis, S. C. Kogan, J. Anastasi, J. D. Crispino, and M. M. Le Beau Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders Blood, July 15, 2007; 110(2): 719 - 726. [Abstract] [Full Text] [PDF]

				M. A. Bogue, S. C. Grubb, T. P. Maddatu, and C. J. Bult Mouse Phenome Database (MPD) Nucleic Acids Res., January 12, 2007; 35(suppl_1): D643 - D649. [Abstract] [Full Text] [PDF]

				R. A. Larson Etiology and Management of Therapy-Related Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 453 - 459. [Abstract] [Full Text] [PDF]